Background. Nucleic acid amplification testing frequently detects conjunctival Chlamydia trachomatis infection in subjects without clinical signs of trachoma. It is unclear whether such subjects are actually infected. We measured chlamydial 16S ribosomal RNA (rRNA) expression, a marker of chlamydial metabolic activity, in comparison with the quantitation of a chlamydial DNA target in subjects exposed to trachoma.
Trachoma is the leading infectious cause of blindness [1] . Recurrent Chlamydia trachomatis infection produces chronic follicular conjunctivitis (clinically active trachoma), which produces conjunctival scarring, entropion, trichiasis, and ultimately blinding corneal opacification. Trachoma is a major public health problem, affecting some of the world's poorest regions. In a global effort to control blinding trachoma, the World Health Organization (WHO) and partners promote the SAFE strategy [2] , which involves provision of surgery for trichiasis, distribution of antibiotics to reduce the burden of chlamydial infection, and face washing and environmental changes to limit transmission.
Identification and treatment of individuals infected with C. trachomatis is necessary for the success of the antibiotic component of this strategy. However, clinical signs of trachoma are unreliable markers of infection. Sensitive PCR assays regularly detect C. trachomatis DNA in clinically healthy people in areas of endemicity [3] [4] [5] . Whether these individuals harbor infection of epidemiological significance is unknown. Studies using quantitative real-time PCR assays for detection of omp1 (a single-copy gene on the C. trachomatis chromosome) to estimate conjunctival chlamydial infection load in members of communities in which infection is endemic found highly skewed distributions; most individuals had relatively low numbers of copies of omp1, whereas a few individuals had many hundreds of thousands of copies of omp1 [6] [7] [8] . The detection of low-level omp1 DNA in these studies might reflect the high sensitivity of DNA amplification assays for subjects with transient inoculations or environmental or physical contamination, rather than established infection. It is unclear how far detection of ocular chlamydial DNA reflects productive infection at the conjunctival surface.
Chlamydiae species exist in 2 principal forms in the developmental cycle established in tissue culture systems [9] . The elementary body is the metabolically inactive, infectious, extracellular form in which genomic DNA is condensed and transcription is limited or absent. On infection of the host cell, the elementary body transforms into the reticulate body form, becoming metabolically active and dividing by binary fission. Chlamydial 16S rRNA is one of the most prominent genes expressed when elementary bodies transform into actively replicating reticulate bodies, and its high-level expression may, therefore, be a marker for actively replicating or viable organisms [10] [11] [12] . As a component of the chlamydial ribosome, it is vital for normal functioning of the organism. Besides being a marker for in vitro metabolic activity, 16S rRNA expression is proportionate to the number chlamydial organisms present [12] .
To better elucidate the relationship between established conjunctival chlamydial infection and DNA detection, we studied expression of chlamydial 16S rRNA in conjunctival samples from a community in which trachoma was endemic in relation to quantitative detection of omp1 DNA, clinical features, and parameters associated with trachoma transmission.
METHODS
Ethical permission. This study was conducted in accordance with the Declaration of Helsinki. It was approved by the Gambian Government/Medical Research Council Joint Ethics Committee. Informed consent was a prerequisite.
Community survey. The study was conducted in 2 Gambian villages. Following household survey and census, all individuals normally resident in the villages were enrolled. Each individual's age, sex, ethnic group, and sleeping room were recorded. Environmental and socioeconomic indicators were recorded.
Clinical assessment. An ophthalmologist graded the left eye of each subject for trachoma, using the WHO Trachoma Grading System [13] . Clinically active trachoma was defined as either a follicular score of 2 or 3 or a papillary score of 3, equivalent to "trachomatous inflammation, follicular" and "trachomatous inflammation, intense," respectively, according to the WHO Simplified Trachoma Grading System [14] . The conjunctiva was anaesthetised with proxymetacaine 0.5% eye drops (Minims; Chauvin Pharmaceuticals). Two swab samples were collected from the left tarsal conjunctival surface (Dacron polyester-tipped swab; Hardwood). Sampling was standardized as 4 horizontal passes across the conjunctiva, with a one-quarter turn between each pass. The first sample, which was used for RNA isolation, was stabilized in 0.2 mL of RNALater (Ambion). The second sample, which was used for DNA isolation, was collected into a dry tube. Samples were kept on ice until transfer to Ϫ20ЊC storage later the same day.
RNA extraction. Total RNA was extracted using RNeasy Mini Kit (Qiagen) according to manufacturer's instructions. In brief, samples were vortexed in 350 mL of RLT buffer, cellular material was homogenized by centrifugation through a QIAshredder, mixed with 350 mL of 70% ethanol, and centrifuged through an RNeasy spin column. The column was washed twice with 350 mL of RW1 and twice with 500 mL of RPE, was dried by centrifugation, and RNA was eluted with 50 mL of RNasefree water. Extracted RNA was stored at Ϫ80ЊC. Total RNA was measured using RiboGreen RNA quantitation kit (Molecular Probes) according to the manufacturer's instructions. Microplates were read on a SpectraMax plate reader (Molecular Devices).
Quantitation of C. trachomatis 16S rRNA. C. trachomatis 16S rRNA expression was quantitated in duplicate by real-time RT-PCR using QuantiTect SYBR Green RT-PCR kit (Qiagen). Each reaction contained 12.5 mL of QuantiTect SYBR Green RT-PCR Master Mix, 1 mL (final concentration, 0.5 mmol/L) each of forward (GGAGAAAAGGGAATTTCACG) and reverse (TCCACATCAAGTATGCATCG) primers, 8.25 mL of water, 0.25 mL of QuantiTect RT Mix, and 2 mL of extracted RNA sample. Samples were tested in duplicate on an ABI 5700 (Applied Biosystems). RNA was reverse transcribed by incubation at 50ЊC for 30 min, followed by heating at 95ЊC for 15 min to activate HotStarTaq DNA Polymerase, 45 cycles of denaturation at 94ЊC for 15 s, annealing at 57ЊC for 30 s, extension at 72ЊC for 30 s, and finally data acquisition after 75ЊC for 15 s. Meltingpoint analysis was performed on the product.
A standard calibration curve was generated with each run by quantitation of a series of 10-fold dilutions of C. trachomatis 16S rRNA cDNA target, from 10 6 to 10 copies/mL. A concentrated solution of target DNA was first produced by PCR amplification of 16S rRNA cDNA, and the concentration was determined using a PicoGreen assay (Molecular Probes). The number of copies of the 173-bp 16S rRNA cDNA product was estimated using the concentration, Avogadro's number, and the molecular mass of a single base pair in daltons. Serial dilutions of the 16S rRNA product were made in ultra-pure autoclaved water containing 2 ng/mL herring sperm DNA (Sigma) and stored at Ϫ20ЊC.
Quantitation of C. trachomatis omp1 DNA. DNA was extracted from the second swab sample using the Amplicor CT/ NG kit (Roche) by a previously described methodology [6] . An aliquot of Amplicor DNA extract for each sample was further purified and concentrated using the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's instructions. The C. trachomatis omp1 copy number in the purified extract was estimated by real-time PCR performed on an ABI 5700 Sequence Detection System [6] . Data analysis. Estimated quantities of omp1 and 16S rRNA are expressed as number of copies per swab. Data were analyzed using Stata software, version 7 (Stata). A multivariable logistic regression model for infection was developed that used generalized estimating equations to take into account clustering of infection at compound level [6] .
RESULTS

Study population.
Two hundred forty-eight people from 2 villages in which trachoma was endemic participated in the study (79% of the total population of the 2 villages). Most (91%) of those not participating in the study had travelled. Subjects were of Wolof ethnicity. Median age was 12 years (interquartile range, 4-25 years), and 59.3% of the subjects were female. Forty-two individuals had clinically active trachoma. All families had access to water within a few minutes walk of their compound throughout the year. One family had a latrine.
Comparison of the assays for C. trachomatis detection. C. trachomatis nucleic acid was detected in 49 (19.8%) and 17 (6.8%) of the samples by omp1 quantitative PCR and 16S rRNA quantitative RT-PCR, respectively. Expression of 16S rRNA was detected in 16 (32%) of 49 samples containing detectable chlamydial omp1 DNA and in 1 (0.5%) of 199 samples without detectable chlamydial omp1 DNA (table 1) .
Infection load distributions. Distributions of estimated number of copies of omp1 DNA and 16S rRNA are shown in table 2. The distribution of the number of copies of omp1 was skewed; many individuals had very low levels. For subjects for whom both assays had positive results, the estimated number of copies was positively correlated ( ), and the estimated r p 0.61 number of copies of 16S rRNA was ∼2 orders of magnitude greater than the estimated number of omp1 copies (data not shown). The 33 subjects for whom omp1 DNA but not 16S rRNA was detected had significantly fewer copies of omp1 (geometric mean number of copies, 9.53; 95% CI, 7.7-11.7) than did the 16 subjects for whom both 16S rRNA and omp1 DNA were detected (geometric mean number of copies, 4118; 95% CI, 954-17,782) (figure 1).
Infection and clinically active disease. The relationship between clinically active trachoma and detection of C. trachomatis omp1 DNA and 16S rRNA is presented in table 3. Less than one-half of those subjects with active trachoma had detectable levels of omp1 DNA or 16S rRNA. Active trachoma was present in 14 (82%) of 17 subjects with detectable 16S rRNA, compared with 28 (12%) of 231 subjects without detectable 16S rRNA (relative risk, 6.79; 95% CI, 4.5-10.25;
). In contrast, P ! .00001 only 18 (37%) of 49 subjects with detectable levels of omp1 DNA had clinically active trachoma, compared with 24 (12%) of 199 subjects without detectable levels of omp1 DNA (relative risk, 3.05; 95% CI, 1.8-5.15;
). Thus, clinical signs of P ! .0001 trachoma were more strongly associated with 16S rRNA expression than with detection of chlamydial omp1 DNA.
Load of infection and clinical disease. For both assays, load of infection was higher among those subjects with signs of active trachoma (table 4). Increasing severity of conjunctival inflammation and follicle scores was associated with increasing 16S rRNA load. There was a less marked trend for omp1 load (table 4) .
Load of infection and age. Infection-particularly infection associated with a high number of omp1 and 16S rRNA copies-was concentrated in children.There were several adults with generally low omp1 loads, whereas chlamydial 16S rRNA was detected only in children, with the exception of a single 27-year-old woman with active trachoma (figures 2 and 3) .
Risk factors for infection. Univariate associations between risk factors and detection of chlamydial nucleic acid are presented in table 5. In this analysis, individuals in whom either 16S rRNA or omp1 DNA were detected are compared with individuals who had negative results according to the same test. In addition, individuals who had results positive for omp1 and negative for 16S rRNA were separately compared with individuals who had negative results for both tests. Expression of 16S rRNA was strongly associated with clinically active disease and with the presence of another individual with active disease in the same room. Detection of omp1 DNA was less strongly associated with active disease. In individuals with test results positive for omp1 and negative for 16S rRNA, the presence of omp1 DNA was not associated with active disease. A multivariable logistic regression model for 16S rRNA expression, adjusted for compound level clustering of infection by generalized estimating equations, was developed (table 6) . Clinically active disease and the presence of another individual with active disease in the same room were associated with detection of 16S rRNA.
Measurement of total RNA. Most samples had a good yield of RNA, with a median concentration 12.5 ng/mL (interquartile range, 8.1-19.1 ng/mL; total range, 1.0-81.8 ng/mL). There was no significant evidence that estimates of chlamydial 16S rRNA expression were dependent on total RNA yield (data not shown). Marginally greater amounts of total RNA were realized from individuals with inflamed conjunctivae, but this was not statistically significant (data not shown).
DISCUSSION
This study demonstrated expression of C. trachomatis 16S rRNA in conjunctival samples obtained from members of a Gambian community in which trachoma was endemic with use of quantitative RT-PCR. 16S rRNA was detected in less than one-half of subjects with detectable levels of C. trachomatis omp1, and it was much more strongly associated with active disease than was omp1. Detection of 16S rRNA was associated with higher omp1 levels. In contrast, detection of chlamydial DNA in the absence of 16S rRNA was associated with low loads of omp1 and normal clinical examination findings.
In situ hybridization studies of C. trachomatis 16S rRNA expression in conjunctival samples obtained from primate models and of natural disease in humans suggested that C. trachomatis 16S rRNA expression was a good marker of chlamydial infection; 16S rRNA has been shown to be detectable even when the results of direct immunofluorescence tests are negative [15, 16] . Expression of 16S rRNA is necessary for the transformation of chlamydial elementary bodies to reticulate bodies. Without ribosomes, new proteins cannot be synthesized. In vitro studies using real-time PCR have demonstrated a rapid increase in 16S rRNA expression during the first 8 h after C. trachomatis infection in cell culture [12] . The amount of 16S rRNA expressed in reticulate bodies was ∼2 orders of magnitude greater than the number of gene copies in the same samples. There are conflicting data as to whether 16S rRNA is normally detectable in elementary bodies. Some studies have not found 16S rRNA in elementary bodies, whereas other studies have found up to 10 3 molecules of 16S rRNA [10, 11] . However, expression is greatly increased in the replicating reticulate body stage, in which it reflects the total number of organisms present [12] . Thus, 16S rRNA expression in tissue culture marks the phase of metabolic activity and active replication in the chlamydial developmental cycle. Our data suggest that, in subjects exposed to ocular C. trachomatis infection, detection of chlamydial metabolic activity is strongly associated with clinical signs of active disease and is consistent with the presumption that established productive infection is a prerequisite for signs of disease to develop.
Consistent with this, studies of a primate model of trachoma found that signs of disease could not be provoked in previously sensitized animals by repeated conjunctival challenge with formalin-or UV-inactivated elementary body preparations or with specific purified surface antigens [17] . However, an inflammatory NOTE. F2/3, follicular score of 2 or 3; P3, papillary score of 3; TF, trachomatous inflammation, follicular; TI, trachomatous inflammation, intense. a According to the World Health Organization Trachoma Grading System [13] .
response was elicited by a soluble extract derived from replicating organisms that was subsequently found to contain a chlamydial heat shock protein now designated Hsp60 or groEL [17] [18] [19] . This suggests that the inflammatory response underlying the clinical signs of trachoma is not attributable to repeated exposure to chlamydial surface antigens (or dead organisms), but that an established infection (or an antigenic product derived from living organisms) is required to initiate it. It has been suggested that 16S rRNA is an indicator of viability; a study found that 16S rRNA became rapidly undetectable after treatment of C. trachomatis cervical infection, whereas C. trachomatis DNA persisted much longer [20] . Among individuals in whom C. trachomatis DNA but not 16S rRNA was detected, we found that multiplicity of infection was low and that there was no association with clinical disease. This suggests that transient inoculations of the conjunctiva with small numbers of nonviable organisms readily occur in this environment through direct or indirect contact with individuals with productive infection but that this does not usually provoke disease. In this setting, eye-seeking flies have been implicated in trachoma transmission, and individuals may experience hundreds of fly-eye contacts daily [21] [22] [23] . These data are consistent with the idea that such mechanical transmission of trachoma via fly-eye contact is an inefficient process, which often results in the inoculation of small numbers of dead or subviable organisms but rarely results in the establishment of new disease. Alternatively, detection of low-level chlamydial DNA but not RNA in clinically healthy adults could be due to an effective immune response that suppresses organism replication. We cannot exclude the possibility that the 16S rRNA assay is less sensitive than the omp1 assay when testing ocular samples. RNA is readily degraded; however, the RNA stabilization and extraction systems used here are well established. Total RNA levels were satisfactory, and there was no evidence that lower yields of total RNA were associated with lower levels of chlamydial 16S rRNA. Samples containing chlamydial 16S rRNA were usually strongly positive, with no samples yielding results close to the limits of detection. Human RNA targets have been readily reverse transcribed and quantitated in all samples in this study [24] .
The use of a second swab sample to measure DNA level was necessary for technical reasons and could have introduced systematic bias. However, although it was not possible in this study to evaluate effect of swab sample order on C. trachomatis RNA and DNA estimations, the data suggest that it is possible to measure significant omp1 loads in the second swab sample. omp1 DNA that is measured in this way gives data consistent with previous studies conducted in this environment, and a study in which additional swab samples were collected found excellent agreement between laboratory test results for the first and second samples [6, 8, 25] . It might also be suggested that low-level omp1 DNA could arise through contamination during sample collection or processing. Careful sample handling at all stages was designed to avoid this. If carry-over contamination occurred at the time of examination from individuals with active infections, we might expect low levels of 16S rRNA to be found in some of the samples, but this was not the case. The detection of low-level omp1 DNA more likely reflects frequent conjunctival "contamination" by low-level transmission of small numbers of organisms.
Current attempts to eliminate blinding trachoma as a public health problem use the SAFE strategy. The WHO recommends community-wide antibiotic treatment if 110% of children aged 1-9 years have active trachoma. At least 3 annual rounds of mass treatment should be given to the entire community. Annual treatment should continue until the prevalence of active trachoma has decreased to !5% in this age group. However, this and other recent studies involving communities in The Gambia and Nepal, where trachoma has a focal distribution, have found that clinical signs of trachoma are a poor predictor of ocular C. trachomatis infection [6, 26] . In some villages that met WHO treatment criteria, not a single person was infected with C. trachomatis. This may be due to nonchlamydial bacterial infection causing conjunctival inflammation. A recent study from Ethiopia, where trachoma is hyperendemic, found that both clinical interobserver reliability and the correlation of clinical examination findings with laboratory evidence of infection were modest [25] . Following mass treatment, clinical signs correlate even less well with infection, compared with before mass treatment is received [8, 27, 28] . Signs may persist for several years after infection has been eliminated from the community. If WHO recommendations were followed, this would lead to administration of systemic or topical antibiotic to large numbers of people who did not require treatment.
An affordable laboratory test for ocular C. trachomatis that could be used in the field would be very useful. However, our study suggests that it may be preferable to base such testing on markers of viable, metabolically active organisms. 16S rRNA may be detected with use of rapid tests based on either nucleic acid sequence-based amplification or transcription-mediated amplification [20, 29] . Alternatively, antigens produced by metabolically active organisms could be targeted. Additional studies may clarify this interpretation, assess response to treatment, and establish whether detecting 16S RNA has utility for targeting treatment or assessing response. Potential conflict of interest. All authors: no conflicts.
